Reuters logo
BRIEF-Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy
September 29, 2016 / 12:32 PM / a year ago

BRIEF-Catabasis Pharma & Sarepta Therapeutics to collaborate in Duchenne muscular dystrophy

Sept 29 (Reuters) - Catabasis Pharmaceuticals Inc :

* Collaboration to study exon skipping treatment by Sarepta with co’s oral NF-KB inhibition treatment in mouse model of DMD

* Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy

* Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy Source text for Eikon: Further company coverage: ;))

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below